Coherus BioSciences (CHRS) announced a clinical collaboration with STORM Therapeutics (STORM) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI in a Phase 1b/2 study for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma and endometrial cancer. Coherus will provide LOQTORZI to STORM, which will be the sponsor of the Phase 1b/2 combination trial.
The phase 1b study will evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI to determine the safety and efficacy of the combination. The phase 2 portion of the study will evaluate expansion cohorts in NSCLC, HNSCC, endometrial cancer and melanoma, in up to 188 patients in the United States.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com